Project Grant R01HL183978
Award Date 8/15/26
Completion Date 4/30/28
Dollars Obligated $2.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Berkeley, CA 94720, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health within the Department of Health and Human Services, awarded J. David Gladstone Institutes $925,796 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop machine learning methods for identifying noncoding genetic variants that cause congenital heart disease. Gladstone will create a deep learning toolkit to predict how rare and de novo noncoding...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $779,600 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the developmental mechanisms that direct cardiac cell diversification and left ventricle morphogenesis. The research employs single-cell transcriptomic analyses and lineage tracing in mouse embryos to define the gene regulatory networks controlling how diverse cardiac cell types emerge from...
- The National Heart, Lung, and Blood Institute awarded J. David Gladstone Institutes $1,585,727 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate epigenomic mechanisms of cardiac fibrosis and heart failure. The project tests the hypothesis that the transcriptional regulator Meox1 functions as a key driver of fibroblast activation, myocardial fibrosis, and heart failure pathogenesis, leveraging novel genetic mouse models, cell lines, and...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded the J. David Gladstone Institutes $1,569,656 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate chromatin regulation of immune cells in myocardial inflammation, with performance through May 31, 2030. The project elucidates BRD4-mediated chromatin and gene regulatory networks controlling monocyte differentiation and macrophage function during myocardial infarction, with the goal of...
- The National Heart, Lung, and Blood Institute awarded Beckman Research Institute of The City of Hope $697,806 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrative machine learning approaches that decode cardiomyocyte subtype dynamics in heart failure progression. The research addresses molecular mechanisms governing the transition from adaptive cardiac hypertrophy to pathological heart failure. The recipient will generate and analyze...
- The National Heart, Lung, and Blood Institute awarded the Trustees of Boston University $849,790 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decode regulatory variants in cardiovascular disease through functional annotation of non-coding variants associated with CVD. The recipient will characterize non-coding regulatory variants and their mechanisms using high-throughput experimental approaches in human cardiomyocytes. Aim 1 encompasses biophysical...
- The National Heart, Lung, and Blood Institute awarded The University of Chicago $817,976 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop single molecule footprinting methods for studying gene regulation in cardiac differentiation and disease. The recipient will combine methyltransferase-based chromatin measurement with native long-read sequencing to assess chromatin accessibility, nucleosome positioning, transcription factor binding, and DNA...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $124,688 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decode the gene regulatory network of mammalian cardiac maturation. The award funds a K99/R00 research project investigating the molecular mechanisms driving postnatal cardiac development. During the K99 phase, the recipient will characterize epigenomic changes in the mouse heart during...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $768,912 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify and validate genetic variants associated with cardiac differentiation and congenital heart disease. The research integrates artificial intelligence with genome engineering to discover intrinsic gene regulatory networks governing heart development. Stanford will employ a base-resolution neural network...
- The National Heart, Lung, and Blood Institute (NHLBI) at the Department of Health and Human Services awarded The Leland Stanford Junior University $755,271 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop, validate, and clinically evaluate a magnetic resonance imaging method for assessing blood flow hemodynamics in pediatric and young adult congenital heart disease patients. The project will augment 4D-flow MRI capabilities to enable direct...